The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions-notably <i>BRCA1/2</i> testing in ovarian, breast, pancreatic and prostate cancers. This evidence concerns the gene BRCA1 and Familial prostate cancer.